MSD Responds to NICE Publication HTTA329 - Introducing Biosimilar Versions of Infliximab

Aug 13, 2015, 13:43 ET from MSD

LUCERNE, Switzerland, August 13, 2015 /PRNewswire/ --

NICE recently published HTTA329 as a resource to help those NHS organisations in the UK which may be planning their approach to the use of biosimilars. MSD's response to this publication is below:

The evidence base for switching stable Remicade® patients to biosimilar infliximab remains limited and inconclusive - data from small scale local observational studies with relatively small numbers of patients and short term duration have been shared at international congresses.[1],[2]

     (Logo: http://photos.prnewswire.com/prnh/20141215/720768 )

MSD advocates the need for larger scale, more robust studies (i.e. randomized, double-blinded and properly powered) to provide more evidence on efficacy, safety and immunogenicity outcomes of switching stable Remicade patients.

Our position is consistent with that of scientific societies such as EULAR, ECCO, ESPGHAN and ACR, which state that the principal driver for decisions is sound scientific evidence and that patients responding to their therapy well should be allowed to continue their current biologic treatment.[3-6]

The NICE publication HTTA329 is a resource to help those NHS organisations in the UK which may be planning their approach to the use of Biosimilars.[7] It does not represent mandatory guidance in the UK and does not carry the same authority as a reference document for other countries.*

MSD welcomes the emphasis from NICE on the need for brand name prescribing of biologics, informed patient consent for switching medicines, and the decision remaining with the prescribing clinician.[7] We also welcome the statement that biosimilars and their originators are not interchangeable, and that patient outcomes should be monitored and recorded.[7] However, the NICE document is not consistent with the professional and patient group positions in the UK, Europe, and USA, which state that stable patients should not be switched on the basis of cost alone.[3-6],[8-11]

While the examples from centres in the UK within this resource offer some methodology for the use of biosimilar infliximab in new and existing patients, they do not demonstrate the consequences of large-scale switching in terms of patient outcomes. MSD joins other stakeholders in awaiting further data from the monitoring and evaluation of patients in these two programmes. Until then, MSD believes it is premature to draw conclusions from these case studies.

*NICE's position statement in January 2015 states that biosimilars will be considered in the context of a Multiple Technology Appraisal, in parallel with their reference products in the indication under consideration, and this has not changed.[12]

Notes to Editors:      

About MSD 

At MSD we believe the most important thing we make is a difference. We operate in more than 140 countries and through our prescription medicines, vaccines, biologic therapies, and animal health products we work with customers to bring innovative healthcare solutions to those who need them the most. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information visit http://www.msd-uk.com. The company is known as Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada. Everywhere else, we are known as MSD. 

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA 

This press statement of Merck & Co., Inc., Kenilworth, NJ, USA  (the "Company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval;  the Company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The Company's undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company's 2014 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (http://www.sec.gov ).

References 

  1. ECCO. Poster Presentations (2015): https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015.html  
  2. EULAR. Session Index (2015). http://www.abstracts2view.com/eular/sessionindex.php  
  3. EULAR. BIOSIMILARS: WHAT DO PATIENTS NEED TO CONSIDER? April 2015. Available from: http://www.eular.org/myUploadData/files/Biosimilars_2015.pdf  
  4. Silvio Danese, Fernando Gomollon on behalf of the Governing Board and Operational Board of ECCO, (2013), ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) , Journal of Crohn's and Colitis , 586-589 , 7
  5. de Ridder L., Waterman M, Turner D et al. ESPGHAN Paediatric IBD Porto Group. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr Jul 6 2015 (in print). Available from: http://journals.lww.com/jpgn/Abstract/publishahead/Use_of_Biosimilars_in_Paediatric_Inflammatory.97858.aspx  
  6. American College of Rheumatology. Position statement on biosimilars. March 2015 Available from: http://www.rheumatology.org/About-Us/Newsroom/Press-Releases/ArticleType/ArticleView/ArticleID/33
  7. NICE. Introducing biosimilar versions of infliximab: Inflectra and Remsima. 31 July 2015. Available from : https://www.nice.org.uk/guidance/htta329
  8. British Society for Rheumatology. Position statement on biosimilar medicines (February 2015). Available from: http://www.rheumatology.org.uk/about_bsr/press_releases/bsr_supports_the_use_of_biolsimilars_but_recommends_measures_to_monitor_safety.aspx
  9. BSG. IBD Section Statement on Biosimilar drugs Available from: http://www.bsg.org.uk/images/stories/docs/clinical/guidance/biosimilars_final2014.pdf
  10. NRAS position paper on biosimilar medicines. Available from: http://www.nras.org.uk/data/files/About%20RA/How%20is%20RA%20managed/NRAS%20Biosimilars%20Position%20Paper%20Final.pdf
  11. CCUK. Biosimilars - potential new drug treatments for Inflammatory Bowel Disease. http://www.crohnsandcolitis.org.uk/whats-new/biosimilars-potential-new-drug-treatments-for-inflammatory-bowel-disease
  12. NICE. NICE's biosimilar position statement http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/biosimilars-statement.pdf  

 

BIOS-1158638-0000

Date of preparation: August 2015

SOURCE MSD